Constantine Chinoporos

CIK: 0002014509

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)2 (28.6%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (42.9%)

Compensation grants

Other (G, F, J, C, D, …)2 (28.6%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

ENGN

enGene Therapeutics Inc.

Officer

GERN

GERON CORP

Director

APLT

Applied Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (7 total)

GERN
GERON CORP
Mar 25, 2026
Award(A)
Stock Option (Right to Buy)
Direct
270K shares-
APLT
Applied Therapeutics, Inc.
Feb 3, 2026
Disposition(D)
Direct
1M shares-
APLT
Applied Therapeutics, Inc.
Feb 3, 2026
Tender Offer(U)
Direct
57.1K shares-
APLT
Applied Therapeutics, Inc.
Dec 19, 2025
Award(A)
Direct
437.5K shares-
APLT
Applied Therapeutics, Inc.
Mar 24, 2025
Award(A)
Direct
350K shares-
APLT
Applied Therapeutics, Inc.
Mar 4, 2025
Sale(S)
Direct
447 shares at avg. $0.44$196.68
APLT
Applied Therapeutics, Inc.
Feb 6, 2025
Sale(S)
Direct
28.1K shares at avg. $0.61$17K

		Type	Shares	Price		Ownership
Mar 25, 2026	GERN GERON CORP	Award(A) Stock Option (Right to Buy)	270,000	-	-	Direct
Feb 3, 2026	APLT Applied Therapeutics, Inc.	Disposition(D)	1,000,000	-	$0	Direct
Feb 3, 2026	APLT Applied Therapeutics, Inc.	Tender Offer(U)	57,111	-	$0	Direct
Dec 19, 2025	APLT Applied Therapeutics, Inc.	Award(A)	437,500	-	$0	Direct
Mar 24, 2025	APLT Applied Therapeutics, Inc.	Award(A)	350,000	-	-	Direct
Mar 4, 2025	APLT Applied Therapeutics, Inc.	Sale(S)	447	$0.44	$197	Direct
Feb 6, 2025	APLT Applied Therapeutics, Inc.	Sale(S)	28,117	$0.61	$17,151	Direct

1-7 of 7 transactions

About Chinoporos Constantine

Chinoporos Constantine (SEC CIK 0002014509) files insider reports with the SEC as Interim Chief Business Officer of enGene Therapeutics Inc. (ENGN), Director of GERON CORP (GERN) and Officer of Applied Therapeutics, Inc. (APLT).

Signal8 holds 7 ownership filings by Chinoporos Constantine (2 Form 3, 5 Form 4), filed between Feb 7, 2025 and Jul 22, 2026. Those filings report 7 transactions, from Feb 6, 2025 to Mar 25, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Chinoporos Constantine's filings is in FOSTER CITY, CA.

Recent filings by Chinoporos Constantine

Mar 25, 2026: Grant or award of GERN derivative securities (Form 4, code A).
Feb 3, 2026: Disposition to issuer transaction of APLT shares (Form 4, code D).
Feb 3, 2026: Tender of shares transaction of APLT shares (Form 4, code U).
Dec 19, 2025: Grant or award of APLT shares (Form 4, code A).
Mar 24, 2025: Grant or award of APLT shares (Form 4, code A).

Other insiders filing for enGene Therapeutics Inc. (ENGN)

Grossman William, Interim Chief Medical Officer
Richton Kathleen P., SVP, Finance and Treasurer
Astley-Sparke Philip, Director
BRUNK GERALD A, Director
Glickman Richard M, Director
HASTINGS PAUL J, Director

How to read Form 4 transaction codes